
The major focus of the alliance will be biomarkers, characteristic changes in the brain and spinal fluid, that physicians can use to diagnose Alzheimer's disease and track its response to treatment. “Alzheimer’s disease is already a huge public health problem that is increasing exponentially," says David M. Holtzman, M.D., the Andrew B. and Gretchen P. Jones Professor and chair of the Department of Neurology at the School of Medicine, and neurologist-in-chief at Barnes-Jewish Hospital. "To prevent this disease with new treatments that are currently on the horizon, we need better ways to diagnose the disease before people become cognitively impaired. We are pleased to be collaborating with AstraZeneca on this important initiative.”... AstraZeneca's Press Release -